{
  "id": 15136466,
  "title": "Baek Urges Review of Drug Price Premiums Excluding Korean-Made APIs From Affiliates",
  "url": "https://urgent.news/2026/10/17/baek-urges-review-of-drug-price-premiums-excluding-korean-made-apis",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-17T06:32:54.000Z",
  "source": {
    "name": "Korea IT Times",
    "slug": "korea-it-times",
    "url": "https://www.koreaittimes.com/news/articleView.html?idxno=158237"
  },
  "original_language": "en",
  "account": null,
  "summary": "Rep. Baek Sun-hee from the Rebuilding Korea Party has called for a review of drug price premiums, focusing on whether Korean-made APIs qualify for preferential pricing when the ingredient producer and the finished drug’s marketing authorization holder are separate companies. During a National Assembly audit in Seoul on October 16, Baek questioned why no companies currently meet the requirement tying API production to the finished drug authorization holder’s own manufacturing facility. This debate stems from concerns about the eligibility rules reflecting production divided among affiliated companies and ensuring continued compliance.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}